Integra LifeSciences (IART) Q1 Earnings Miss Estimates

Core Insights - Integra LifeSciences reported quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.43 per share, and down from $0.55 per share a year ago, representing an earnings surprise of -4.65% [1] - The company posted revenues of $382.65 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.13% and up from $368.87 million year-over-year [2] - Integra shares have declined approximately 25.7% since the beginning of the year, compared to a decline of -3.3% for the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.58 on revenues of $417.75 million, and for the current fiscal year, it is $2.46 on revenues of $1.68 billion [7] - The estimate revisions trend for Integra is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Integra belongs, is currently in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Neuronetics, is expected to report a quarterly loss of $0.13 per share, reflecting a year-over-year change of +51.9%, with revenues anticipated to be $29.24 million, up 67.8% from the previous year [9][10]